Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.
Li Z, Ju X, Lee K, Clarke C, Hsu JL, Abadir E, Bryant CE, Pears S, Sunderland N, Heffernan S, Hennessy A, Lo TH, Pietersz GA, Kupresanin F, Fromm PD, Silveira PA, Tsonis C, Cooper WA, Cunningham I, Brown C, Clark GJ, Hart DNJ. Li Z, et al. Among authors: hart dnj. Haematologica. 2018 Apr;103(4):655-665. doi: 10.3324/haematol.2017.178384. Epub 2018 Jan 19. Haematologica. 2018. PMID: 29351987 Free PMC article.
The Analysis of CD83 Expression on Human Immune Cells Identifies a Unique CD83+-Activated T Cell Population.
Ju X, Silveira PA, Hsu WH, Elgundi Z, Alingcastre R, Verma ND, Fromm PD, Hsu JL, Bryant C, Li Z, Kupresanin F, Lo TH, Clarke C, Lee K, McGuire H, Fazekas de St Groth B, Larsen SR, Gibson J, Bradstock KF, Clark GJ, Hart DN. Ju X, et al. J Immunol. 2016 Dec 15;197(12):4613-4625. doi: 10.4049/jimmunol.1600339. Epub 2016 Nov 11. J Immunol. 2016. PMID: 27837105
Examination of CD302 as a potential therapeutic target for acute myeloid leukemia.
Lo TH, Abadir E, Gasiorowski RE, Kabani K, Ramesh M, Orellana D, Fromm PD, Kupresanin F, Newman E, Cunningham I, Hart DNJ, Silveira PA, Clark GJ. Lo TH, et al. Among authors: hart dnj. PLoS One. 2019 May 10;14(5):e0216368. doi: 10.1371/journal.pone.0216368. eCollection 2019. PLoS One. 2019. PMID: 31075107 Free PMC article.
Antibody therapy for acute myeloid leukaemia.
Gasiorowski RE, Clark GJ, Bradstock K, Hart DN. Gasiorowski RE, et al. Br J Haematol. 2014 Feb;164(4):481-95. doi: 10.1111/bjh.12691. Epub 2013 Dec 10. Br J Haematol. 2014. PMID: 24321020 Free article. Review.
Dendritic cells as cancer therapeutics.
Bryant CE, Sutherland S, Kong B, Papadimitrious MS, Fromm PD, Hart DNJ. Bryant CE, et al. Among authors: hart dnj. Semin Cell Dev Biol. 2019 Feb;86:77-88. doi: 10.1016/j.semcdb.2018.02.015. Epub 2018 Mar 21. Semin Cell Dev Biol. 2019. PMID: 29454038 Review.
The cell surface phenotype of human dendritic cells.
Clark GJ, Silveira PA, Hogarth PM, Hart DNJ. Clark GJ, et al. Among authors: hart dnj. Semin Cell Dev Biol. 2019 Feb;86:3-14. doi: 10.1016/j.semcdb.2018.02.013. Epub 2018 Mar 27. Semin Cell Dev Biol. 2019. PMID: 29499385 Review.
Distinguishing human peripheral blood CD16+ myeloid cells based on phenotypic characteristics.
Fromm PD, Silveira PA, Hsu JL, Papadimitrious MS, Lo TH, Ju X, Kupresanin F, Romano A, Hsu WH, Bryant CE, Kong B, Abadir E, Mekkawy A, M McGuire H, Groth BFS, Cunningham I, Newman E, Gibson J, Hogarth PM, Hart DNJ, Clark GJ. Fromm PD, et al. Among authors: hart dnj. J Leukoc Biol. 2020 Feb;107(2):323-339. doi: 10.1002/JLB.5A1119-362RRR. Epub 2019 Nov 21. J Leukoc Biol. 2020. PMID: 31749181
160 results